|

Tucatinib Clinical Trials

10 actively recruiting trials across 8 locations

No change since August 2026

Also known as: ARRY-380, Irbinitinib, ONT-380, TUKYSA, TUKYSA, ONT-380, ARRY-380 +2 more

Pipeline

Phase 1: 1Phase 2: 5Phase 3: 1Phase 1/2: 2Phase 2/3: 1

Top Sponsors

  • The Netherlands Cancer Institute1
  • Seagen, a wholly owned subsidiary of Pfizer1
  • SCRI Development Innovations, LLC1
  • QuantumLeap Healthcare Collaborative1
  • Merck Sharp & Dohme LLC1

Indications

Other2 trials

Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)
Phase 2
Neoadjuvant Trastuzumab, Pertuzumab and Tucatinib Without Chemotherapy in HER2-positive Breast Cancer: the TRAIN-4 Study
Phase 1

Birmingham, Alabama1 trial

PRE-ISPY Phase I/II Oncology Platform Program

The University of Alabama at Birmingham O'Neal Comprehensive Cancer Center

Phase 1/2

Glendale, Arizona1 trial

A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer

Palo Verde Hematology Oncology

Phase 3

Aurora, Colorado1 trial

Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)

University of Colorado Anschutz Medical Campus ( Site 0057)

Phase 1/2

Columbia, Maryland1 trial

Study of Tucatinib and Doxil in Participants With Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer

Maryland Oncology Hematology

Phase 2

Boston, Massachusetts1 trial

The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer

Dana-Farber Cancer Institute

Phase 2

Basking Ridge, New Jersey1 trial

A Study of Tucatinib and Trastuzumab in People With Rectal Cancer

Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)

Phase 2

East Brunswick, New Jersey1 trial

RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive

Astera Cancer Care East Brunswick

Phase 2/3

Houston, Texas1 trial

A Phase II Study of Tucatinib and Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2-positive Metastatic Solid Tumors and Metastases to Brain (TUCATEMEB)

M D Anderson Cancer Center

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.